drug

PF-05180999

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
2 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Trials

2
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
NCT01530529Phase 1Completed
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
NCT01429740Phase 1Completed

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
company
trial
A Study to Assess the Relative Bioavailability of a Modified-Release Formulation of PF-05180999
PHASE1
trial
A Study Of The Safety, Tolerability And Pharmacokinetics Of Single Doses Of PF-05180999 In Healthy Adults
PHASE1
trial
indication
Schizophrenia
indication
Healthy
indication
Schizophrenia Spectrum and Other Psychotic Disorders
indication
Mental Disorders
indication